Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
325 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Currently Recruiting (50)
  • Closed (164)

Medical Condition

  • Show all (1940)
  • Addiction (18)
  • Allergy, Asthma, & Immunology (13)
  • All of Us Research Program - NIH (1)
  • Autoimmune Disorders (28)
  • Blood Disorders (39)
  • Bone & Muscle (10)
  • Cancer (745)
  • Child Development (4)
  • (-) COVID-19 (Coronavirus) (36)
  • Critical Illness (1)
  • Diabetes (21)
  • Ear, Nose and Throat (11)
  • Endocrine & Metabolic Disease (12)
  • Eye (7)
  • Gastrointestinal and Digestive Diseases (25)
  • Hair and Skin Disorders (3)
  • Headaches (5)
  • Healthy Volunteers (183)
  • Heart Disease (128)
  • Infectious Disease (49)
  • Insomnia (2)
  • Kidney Disease (12)
  • Liver Disease (51)
  • Lung Disease (31)
  • Meniere's Disease (1)
  • (-) Neurological Disorders (178)
    • Alzheimer's Disease (39)
    • Brain Tumors (60)
    • Cerebral Palsy (2)
    • Dementia (8)
    • Huntington's Disease (4)
    • Multiple Sclerosis (8)
    • Neuromuscular (10)
    • Neuropathy (12)
    • Parkinson's Disease (3)
  • Nutrition (7)
  • Obesity (9)
  • Obstetrics & Gynecology (53)
  • Pain Management (1)
  • Pediatrics (103)
  • Psychiatric Disorders (65)
  • Rehabilitation (8)
  • Stroke (6)
  • Surgery (7)
  • Transplant (53)
  • Urology (4)
  • Vascular Conditions (10)
Displaying 201 - 214 of 214

Study of Gantenerumab in Subjects with Early Alzheimer's Disease (Prodromal to Mild)

Condition: Neurological Disorders / Alzheimer's Disease
Investigator: Lawrence Honig, MD, PhD
Status: Closed
This is a randomized, double-blind, placebo-controlled, parallel-group study that will evaluate the efficacy and safety of gantenerumab versus placebo in participants with prodromal (very early form) to mild AD. Participants will have a chance of receiving either injections of gantenerumab or placebo as per the visit schedule. The primary efficacy…
Read More

A study for patients at risk for memory loss using study drug solanezumab

Condition: Neurological Disorders / Alzheimer's Disease
Investigator: Karen Bell, MD
Status: Closed
The purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid. The study will also test 1) whether the anti-amyloid treatment can slow evidence of AD-related brain injury on imaging tests to look at brain structure and function and 2) the effect of…
Read More

A Study to Evaluate the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neuropathy

Condition: Neurological Disorders / Neuromuscular
Investigator: Thomas Brannagan, MD
Status: Closed
Small fiber neuropathy is a painful condition caused by damage to the small nerves in your arms andlegs. This damage causes burning, sharp-stabbing and aching pain, amongst other types of pain. It can be sometimes difficult to know the cause of the damage to the small nerves in your arms and legs. In most cases, treatment for small fiber neuropathy is…
Read More

Phase 3 Gene Therapy for Painful Diabetic Neuropathy

Condition: Neurological Disorders / Neuropathy
Investigator: Thomas Brannagan, MD
Status: Closed
You are being considered to participate in this research study because you have type I or II diabetes with current treatment control and, you are experiencing painful diabetic peripheral neuropathy (DPN) in both lower extremities legs.The specific events that result in painful diabetic peripheral neuropathy are not well understood, but high blood sugar,…
Read More

DSC-MRI in Measuring Relative Cerebral Blood Volume for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma

Condition: Neurological Disorders / Brain Tumors
Investigator: Angela Lignelli-Dipple, MD
Status: Closed
The purpose of this research study is to test whether the advanced perfusion MRI done prior to starting Bevacizumab and a few weeks after starting Bevacizumab can determine your response to the treatment better than the standard MRI performed at typical time points. The researchers want to see if this type of advanced MRI is better or the same as what is…
Read More

Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis

Condition: Neurological Disorders / Neuromuscular
Investigator: Thomas Brannagan, MD
Status: Closed
This study is designed to test how well an intravenous human immunoglobulin concentrate, IGIV-C (compared with placebo) improves the ability to taper participant's dose of corticosteroids without causing significant increase in your muscle weakness and worsening MG symptoms. A placebo is a medication that looks like the study medication but has no…
Read More

Study for Critically ill Inpatients at Columbia University Irving Medical Center Who Want to Participate in the Convalescent Plasma Trial

Condition: COVID-19 (Coronavirus)
Investigator: Max O'Donnell, MD, MPH
Status: Closed
If you want to be a plasma donor please go to (https://recruit.cumc.columbia.edu/clinical_trial/1929). The purpose of this research study is to find out whether antibodies collected from the blood of people, who have been infected with the virus SARS-CoV-2 and recovered from COVID-19, can be used to reduce the risk of severe disease or death in people with…
Read More

An observational study for individuals diagnosed with an FTLD disorder as well as members of families with a history of FTLD disorders.

Condition: Neurological Disorders
Investigator: Matthew Harms, MD
Status: Closed
This is an observational study designed to collect information about Frontotemporal Lobar Degeneration (FTLD) disorders. FTLD is a term for a related group of neurodegenerative disorders that cause impairments in personality, cognitive ability, language, and motor function. This study aims to build a reliable clinical research network to support treatment…
Read More

Study of ABBV-321 in Subjects with Advanced Solid Tumors Associated with Overexpression of Epidermal Growth Factor Receptor (EGFR)

Condition: Neurological Disorders / Brain Tumors
Investigator: Andrew Lassman, MD
Status: Closed
This is a two-part research study of an investigational drug called ABBV-321 in subjects with glioblastoma (brain tumor). This study will be conducted in two-parts: 1) Dose Escalation Phase: The purpose of the first part, called a Dose Escalation Phase, is where we will increase the dose of ABBV-321 until we find the highest dose before unmanageable side…
Read More

Study for treating patients with neuropathy using study drug fingolimod

Condition: Neurological Disorders / Neuropathy
Investigator: Thomas Brannagan, MD
Status: Closed
The purpose of this study is to evaluate the efficacy and safety of study drug, fingolimod taken daily compared with a placebo (does not contain active medication) on delaying disability progression in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). The study will consist of 3 periods: a Screening Period (lasting for up to 45…
Read More

INdividualized Screening trial of Innovative Glioblastoma Therapy (INSIGhT)

Condition: Neurological Disorders / Brain Tumors
Investigator: Mary Welch, MD
Status: Closed
This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness ofan investigational drug to learn whether the study drug works in treating a specific disease.Investigational means that the drug is being studied. In this research study, we are looking to compare the effects, good and bad, of the standard of care…
Read More

Treatment of Agitation in Alzheimer's Disease

Condition: Neurological Disorders / Alzheimer's Disease
Investigator: Davangere Devanand, MD
Status: Closed
This NIH funded research study involves a 12-week double blind treatment trial in which Alzheimer's disease (ages 55-95) who have agitation/aggression with or without psychosis (hallucinations or delusions) will receive either low-dose lithium or placebo. Patients are allowed to receive other specific psychiatric medications if needed during the study…
Read More

Study of Cediranib and Olaparib Compared to Bevacizumab in Patients with Recurrent Glioblastoma

Condition: Neurological Disorders / Brain Tumors
Investigator: Mary Welch, MD
Status: Closed
The purpose of this study is to investigate a novel treatment regimen for patients with recurrent Glioblastomas (GBM). In this phase 2 trial, the potentially synergistic action of PARP inhibition and anti-angiogenesis on DNA repair and biomarkers of angiogenesis and DNA repair will be evaluated.
Read More

This study seeks to assess if anti-spike SARS-CoV-2 monoclonal antibodies can prevent COVID in household contacts of individuals with COVID.

Condition: COVID-19 (Coronavirus)
Investigator: Ellen Morrison, MD, MPH
Status: Closed
We are conducting a CoVPN-funded study to understand if monoclonal antibodies can protect people exposed to SARS-COV-2 from developing the COVID-19 disease that it causes. If you live with someone recently diagnosed with COVID, you may be eligible to participate in one or more study visits. At each visit you will be asked to provide blood, nasal, and urine…
Read More

Pagination

  • Previous page ‹‹
  • Page 2
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Terms of Use Privacy Policy ©2025 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science